{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:59:24Z","timestamp":1783339164897,"version":"3.54.6"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsche Krebshilfe,Germany"},{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Bloodstream infections (BSI) due to <jats:italic>Candida<\/jats:italic> spp. significantly contribute to morbidity and mortality among cancer patients. Understanding their clinical course, risk factors, and outcomes compared to bacterial BSI is essential.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>We aim to elucidate the epidemiology and risk factors associated with <jats:italic>Candida<\/jats:italic> BSI compared to bacterial BSI in cancer patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We analyzed epidemiological data of <jats:italic>Candida<\/jats:italic> BSI versus bacterial BSI among cancer patients, primarily with hematological malignancies. Blood cultures were obtained upon clinical suspicion, with species identification by VITEK 2 and MALDI-TOF. Susceptibility testing utilized VITEK 2 or antibiotic gradient tests.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n              <jats:italic>Candida<\/jats:italic> BSI was associated with higher 30-day mortality compared to bacterial BSI (Hazard ratio (HR) 4.5, 95% CI 2.5\u20138.1, p\u2009&lt;\u20090.001) occurring predominantly in patients with relapsed\/refractory disease. Univariate analysis identified risk factors for <jats:italic>Candida<\/jats:italic> BSI: hypoalbuminemia (Odds ratio (OR) 9.13, 95% CI 2.7\u201357, p\u2009=\u20090.003), prior ICU\/MC stay (OR 3.91, 95% CI 1.38\u20139.65, p\u2009=\u20090.005), palliative treatment (OR 3.42, 95% CI 1.52\u20137.4, p\u2009=\u20090.002), parenteral nutrition (OR 2.44, 95% CI 0.9\u20135.5, p\u2009=\u20090.039) and prior allogeneic HSCT (OR 2.28, 95% CI 0.92\u20135.13, p\u2009=\u20090.056). Risk factors identified by multivariate analysis were palliative therapy (OR 5.23, 95% CI 3.14\u20138.71, p\u2009=\u20090.001), hypoalbuminemia (OR 9.02, 95% CI 4.23\u201319.2, p\u2009=\u20090.004), and prior ICU\/IMC stay (OR 4, 95% CI 2.31\u20136.92, p\u2009=\u20090.011). In patients with confirmed <jats:italic>Candida<\/jats:italic> BSI, delayed initiation of antifungal was associated with worse outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Compared to bacterial BSI events, <jats:italic>Candida<\/jats:italic> BSI are associated with significantly higher 30-day mortality, primarily affecting heavily pretreated patients with relapsed or refractory disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s15010-025-02513-z","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T09:19:54Z","timestamp":1743758394000},"page":"1875-1885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Epidemiology and outcomes of Candida spp. bloodstream infections in cancer patients: a comparative retrospective study from a German tertiary cancer center"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9993-9750","authenticated-orcid":false,"given":"Sebastian","family":"Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Janetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius C.","family":"Enssle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hogardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkhard A. J.","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J. G. T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Scheich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"2513_CR1","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258\u201366.","journal-title":"Cancer"},{"key":"2513_CR2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1186\/s12879-021-06243-z","volume":"21","author":"A Amanati","year":"2021","unstructured":"Amanati A, Sajedianfard S, Khajeh S, Ghasempour S, Mehrangiz S, Nematolahi S, et al. Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance. BMC Infect Dis. 2021;21:636.","journal-title":"BMC Infect Dis"},{"key":"2513_CR3","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00277-018-3423-5","volume":"97","author":"S Scheich","year":"2018","unstructured":"Scheich S, Weber S, Reinheimer C, Wichelhaus TA, Hogardt M, Kempf VAJ, et al. Bloodstream infections with gram-negative organisms and the impact of multidrug resistance in patients with hematological malignancies. Ann Hematol. 2018;97:2225\u201334.","journal-title":"Ann Hematol"},{"key":"2513_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/13693786.2011.587211","volume":"50","author":"J Zirkel","year":"2012","unstructured":"Zirkel J, Klinker H, Kuhn A, Abele-Horn M, Tappe D, Turnwald D, et al. Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol. 2012;50:50\u20135.","journal-title":"Med Mycol"},{"key":"2513_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ijantimicag.2006.01.002","volume":"27","author":"AM Tortorano","year":"2006","unstructured":"Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents. 2006;27:359\u201366.","journal-title":"Int J Antimicrob Agents"},{"key":"2513_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s00134-017-4743-y","volume":"43","author":"O Lortholary","year":"2017","unstructured":"Lortholary O, Renaudat C, Sitbon K, Desnos-Ollivier M, Bretagne S, Dromer F, et al. The risk and clinical outcome of candidemia depending on underlying malignancy. Intensive Care Med. 2017;43:652\u201362.","journal-title":"Intensive Care Med"},{"key":"2513_CR7","first-page":"3221","volume":"73","author":"JA Maertens","year":"2018","unstructured":"Maertens JA, Girmenia C, Br\u00fcggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European conference infections in leukaemia. J Antimicrob Chemother. 2018;73:3221\u201330.","journal-title":"J Antimicrob Chemother"},{"key":"2513_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","volume":"97","author":"SC Mellinghoff","year":"2018","unstructured":"Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018;97:197\u2013207.","journal-title":"Ann Hematol"},{"key":"2513_CR9","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00277-021-04541-9","volume":"100","author":"S Weber","year":"2021","unstructured":"Weber S, Magh A, Hogardt M, Kempf VAJ, Vehreschild MJGT, Serve H, et al. Profiling of bacterial bloodstream infections in hematological and oncological patients based on a comparative survival analysis. Ann Hematol. 2021;100:1593\u2013602.","journal-title":"Ann Hematol"},{"key":"2513_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1469-0691.2011.03703.x","volume":"19","author":"R Leclercq","year":"2013","unstructured":"Leclercq R, Cant\u00f3n R, Brown DFJ, Giske CG, Heisig P, MacGowan AP, et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect. 2013;19:141\u201360.","journal-title":"Clin Microbiol Infect"},{"key":"2513_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/jac\/dkp428","volume":"65","author":"PG Higgins","year":"2010","unstructured":"Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010;65:233\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"2513_CR12","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1128\/JCM.02117-12","volume":"50","author":"D Doyle","year":"2020","unstructured":"Doyle D, Peirano G, Lascols C, Lloyd T, Church DL, Pitout JDD. Laboratory detection of enterobacteriaceae that produce carbapenemases. J Clin Microbiol. 2020;50:3877\u201380.","journal-title":"J Clin Microbiol"},{"key":"2513_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"A-P Magiorakos","year":"2012","unstructured":"Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"2513_CR14","doi-asserted-by":"crossref","unstructured":"Hygienema\u00dfnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen St\u00e4bchen. Bundesgesundheitsbl. 2012; 55:1311\u201354.","DOI":"10.1007\/s00103-012-1549-5"},{"key":"2513_CR15","unstructured":"Bakterielle Infektionen und Pneumocystis jiroveci Pneumonie - Prophylaxe [Internet]. Onkopedia. Available from: https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/bakterielle-infektionen-und-pneumocystis-jiroveci-pneumonie-prophylaxe. Accessed 26 Nov 2024."},{"key":"2513_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"2513_CR17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/INF.0000000000001938","volume":"37","author":"I Levene","year":"2018","unstructured":"Levene I, Castagnola E, Haeusler GM. Antibiotic-resistant gram-negative blood stream infections in children with cancer: a review of epidemiology, risk factors, and outcome. Pediatr Infect Dis J. 2018;37:495.","journal-title":"Pediatr Infect Dis J"},{"key":"2513_CR18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1128\/AAC.49.2.760-766.2005","volume":"49","author":"C-I Kang","year":"2005","unstructured":"Kang C-I, Kim S-H, Park WB, Lee K-D, Kim H-B, Kim E-C, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005;49:760\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"2513_CR19","doi-asserted-by":"publisher","first-page":"e202009","DOI":"10.4084\/mjhid.2020.009","volume":"12","author":"B-A Hansen","year":"2019","unstructured":"Hansen B-A, Wendelbo \u00d8, Bruserud \u00d8, Hemsing AL, Mosevoll KA, Reikvam H. Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment. Mediterr J Hematol Infect Dis. 2019;12:e202009.","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"2513_CR20","doi-asserted-by":"publisher","first-page":"S173.e5","DOI":"10.1016\/j.ajic.2008.10.007","volume":"36","author":"M Opilla","year":"2008","unstructured":"Opilla M. Epidemiology of bloodstream infection associated with parenteral nutrition. American J Infect Control. 2008;36:S173.e5-S173.e8.","journal-title":"American J Infect Control."},{"key":"2513_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.chest.2021.08.081","volume":"161","author":"DO Thomas-R\u00fcddel","year":"2022","unstructured":"Thomas-R\u00fcddel DO, Schlattmann P, Pletz M, Kurzai O, Bloos F. Risk factors for invasive Candida Infection in critically Ill patients. Chest. 2022;161:345\u201355.","journal-title":"Chest"},{"key":"2513_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13613-020-00755-8","volume":"10","author":"M Schroeder","year":"2020","unstructured":"Schroeder M, Weber T, Denker T, Winterland S, Wichmann D, Rohde H, et al. Epidemiology, clinical characteristics, and outcome of candidemia in critically Ill patients in Germany: a single-center retrospective 10-year analysis. Ann Intensive Care. 2020;10:142.","journal-title":"Ann Intensive Care"},{"key":"2513_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-2334-5-22","volume":"5","author":"M-F Cheng","year":"2005","unstructured":"Cheng M-F, Yang Y-L, Yao T-J, Lin C-Y, Liu J-S, Tang R-B, et al. Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species. BMC Infect Dis. 2005;5:22.","journal-title":"BMC Infect Dis"},{"key":"2513_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11046-022-00624-x","volume":"187","author":"L Brescini","year":"2022","unstructured":"Brescini L, Mazzanti S, Morroni G, Pallotta F, Masucci A, Orsetti E, et al. Candidemia in internal medicine: facing the new challenge. Mycopathologia. 2022;187:181\u20138.","journal-title":"Mycopathologia"},{"key":"2513_CR25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s15010-016-0924-9","volume":"44","author":"R Luzzati","year":"2016","unstructured":"Luzzati R, Merelli M, Ansaldi F, Rosin C, Azzini A, Cavinato S, et al. Nosocomial candidemia in patients admitted to medicine wards compared to other wards: a multicentre study. Infection. 2016;44:747\u201355.","journal-title":"Infection"},{"key":"2513_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejim.2017.03.005","volume":"41","author":"M Falcone","year":"2017","unstructured":"Falcone M, Tiseo G, Tascini C, Russo A, Sozio E, Raponi G, et al. Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in internal medicine wards: a multicenter study. Eur J Intern Med. 2017;41:33\u20138.","journal-title":"Eur J Intern Med"},{"key":"2513_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s15010-018-1162-0","volume":"46","author":"E Sozio","year":"2018","unstructured":"Sozio E, Pieralli F, Azzini AM, Tintori G, Demma F, Furneri G, et al. A prediction rule for early recognition of patients with candidemia in internal medicine: results from an Italian, multicentric, case\u2013control study. Infection. 2018;46:625\u201333.","journal-title":"Infection"},{"key":"2513_CR28","doi-asserted-by":"publisher","first-page":"2154548","DOI":"10.1080\/19490976.2022.2154548","volume":"14","author":"JL Sprague","year":"2022","unstructured":"Sprague JL, Kasper L, Hube B. From intestinal colonization to systemic infections: Candida albicans translocation and dissemination. Gut Microbes. 2022;14:2154548.","journal-title":"Gut Microbes"},{"key":"2513_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41591-019-0709-7","volume":"26","author":"B Zhai","year":"2020","unstructured":"Zhai B, Ola M, Rolling T, Tosini NL, Joshowitz S, Littmann ER, et al. High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis. Nat Med. 2020;26:59\u201364.","journal-title":"Nat Med"},{"key":"2513_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12967-023-04091-w","volume":"21","author":"E Haroun","year":"2023","unstructured":"Haroun E, Kumar PA, Saba L, Kassab J, Ghimire K, Dutta D, et al. Intestinal barrier functions in hematologic and oncologic diseases. J Transl Med. 2023;21:233.","journal-title":"J Transl Med"},{"key":"2513_CR31","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.3390\/jcm10112508","volume":"10","author":"M Tyszka","year":"2021","unstructured":"Tyszka M, Bili\u0144ski J, Basak GW. Advances in intestinal barrier preservation and restoration in the allogeneic hematopoietic cell transplantation setting. J Clin Med. 2021;10:2508.","journal-title":"J Clin Med"},{"key":"2513_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-024-03756-9","author":"S Wang","year":"2024","unstructured":"Wang S, Li C, Dong Y, Dong W. Approaches for posaconazole therapeutic drug monitoring and their clinical benefits. Eur J Clin Pharmacol. 2024. https:\/\/doi.org\/10.1007\/s00228-024-03756-9.","journal-title":"Eur J Clin Pharmacol"},{"key":"2513_CR33","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1097\/CCM.0000000000005357","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Executive summary: surviving sepsis campaign: international guidelines for the management of sepsis and septic shock 2021. Crit Care Med. 2021;49:1974.","journal-title":"Crit Care Med"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02513-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02513-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02513-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:40:39Z","timestamp":1758721239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02513-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2513"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02513-z","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"15 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the local ethics committee (approval number: SHN-10-2017).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}